within Pharmacolibrary.Drugs.ATC.G;

model G01AG02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0011666666666666668,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0066,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G01AG02</td></tr><td>route:</td><td>intravaginal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Terconazole is a triazole antifungal agent primarily used for the treatment of vulvovaginal candidiasis. It is administered as a topical formulation and is FDA-approved for intravaginal use. Its mechanism of action is through inhibition of fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and thus fungal cell membrane formation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult female subjects using intravaginal administration; values are approximated based on summary statements available from product labels and secondary literature, as no detailed compartmental PK modeling for terconazole in humans is published.</p><h4>References</h4><ol><li><p>Iavazzo, C, et al., &amp; Falagas, ME (2011). Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. <i>Journal of women&#x27;s health (2002)</i> 20(8) 1245–1255. DOI:<a href=\"https://doi.org/10.1089/jwh.2010.2708\">10.1089/jwh.2010.2708</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21774671/\">https://pubmed.ncbi.nlm.nih.gov/21774671</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G01AG02;
